Euro
USD
British Pound
NULL
Product Description
Pertuzumab is a humanized monoclonal antibody that is produced by recombinant DNA technology in CHO cells and targets the extracellular domain of human epidermal growth factor receptor 2 (HER2) by blocking the binding pocket required for dimerization of the receptor and receptor mediated signaling. This prevents binding of HER2 with other HER family members (HER1, HER3, HER4) and thus inhibits cancer cell growth. Developed by Roche and Genentech, Pertuzumab was approved by FDA in 2012 to treat advanced breast cancer. Combination treatment with Trastuzumab and Docetaxel has been recommended for treating patients that have HER2-positive metastatic breast cancer.
Biovision | A2111 | Anti-HER2 (Pertuzumab), Humanized Antibody DataSheet
Antibody Target: HER2
Target Alternative Name: 2C4, rhuMAb-2C4, HER2, HER-2, HER 2, Neu, Ngl, Erbb2, Tkr1, Cd340, Mln 19, HER-2/neu
Tag Line: Pertuzumab is a humanized monoclonal antibody that binds to HER2 receptor and inhibits the binding of HER2 to other HER family members (HER1, HER3, HER4) on cancer cell surface
Category: Primary antibody
Host: CHO cells
Isotype: Human IgG1
Species Reactivities:
Immunogen Sequence: Pertuzumab
Accession #: DB06366
Gene ID:
Appearance: Colorless liquid
Form: Liquid
Concentration:
Formulation: In PBS buffer, pH 7.2
Purification:
Application: Growth inhibition assay, Cell cytotoxicity assay, In vivo studies
Positive Control:
Application And Usages: Growth inhibition assay, Cell Cytotoxicity assay, In vivo studies
Country of Animal Origin: USA
Country of Manufacture: USA
Usage: For Research Use Only! Not to be used in humans.
Handling: The antibody solution should be gently mixed before use.
Western Blot Verified: FALSE
Immunocytochemistry Verified: FALSE
Immunofluorescence Verified: FALSE
Immunoprecipitation Verified: FALSE
FACS Verified: FALSE
ELISA Verified: FALSE
ChIP Verified: FALSE
Dot Blot Verified: FALSE
Flow Cytometry Verified: FALSE
